PLEASANTON, Calif., Sept. 3,
2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq:
TXG), a leader in single cell and spatial biology, today announced
the launch of Chromium Xo, a new addition to its fleet of Chromium
single cell instruments. Designed to meet the needs of researchers
who desire high-quality data on limited budgets, Chromium Xo offers
an affordable entry point into routine, high-performance single
cell analysis.
"Chromium Xo is the latest in a series of 10x innovations
intended to democratize single cell analysis because we never want
researchers to have to settle for anything less than the best,"
said Ben Hindson, Chief Scientific
Officer and Co-founder. "With Chromium Xo, we're not just lowering
the cost barrier; we're empowering more researchers to achieve
high-quality, repeatable results necessary for meaningful
scientific breakthroughs."
Chromium Xo is 10x Genomics' most affordable single cell
instrument, delivering the high-quality data, superior
reproducibility and ease of use that the company's
instrument-powered workflows are known for, at a U.S. list price of
$25,000.
Chromium Xo is specifically designed to run 10x Genomics'
industry-leading GEM-X 3' assay, which provides up to 80% cell
capture and more than 40% higher gene sensitivity compared to
alternative non-10x methods. GEM-X technology also enables
researchers to generate more usable reads to detect more genes with
less sequencing, potentially saving more than 50% on sequencing
costs compared to non-10x methods.
In addition, there is a path for researchers to seamlessly
upgrade to Chromium X to access the full breadth of the company's
single cell portfolio, including assays for FFPE samples and immune
profiling.
With features like automation to partition hundreds of thousands
of cells in minutes and an intuitive push-button interface for
efficient cell processing, Chromium instruments remove many of the
challenges and inconsistencies of manual, instrument-less
workflows. The instrument-powered Chromium platform enables high
data quality and twice the sample recovery as manual methods. In
addition, Chromium instruments streamline the workflow, improve
scalability and enable superior reproducibility, resulting in less
hands-on time, lower labor and experimental costs and faster time
to results compared to alternative single cell workflows.
Added Hindson, "Our ultimate goal is to enable high-performance
single cell analysis for $100 per
sample. With Chromium Xo and what's planned in our pipeline, we are
continuing to drive our Chromium technology in that direction so
more researchers can rely on these methods more often."
Chromium Xo is now shipping globally.
About 10x Genomics
10x Genomics is a life science
technology company building products to accelerate the mastery of
biology and advance human health. Our integrated solutions include
instruments, consumables and software for single cell and spatial
biology, which help academic and translational researchers and
biopharmaceutical companies understand biological systems at a
resolution and scale that matches the complexity of biology. Our
products are behind breakthroughs in oncology, immunology,
neuroscience and more, fueling powerful discoveries that are
transforming the world's understanding of health and disease. To
learn more, visit 10xgenomics.com or connect with
us on LinkedIn or X (Twitter).
Forward Looking Statements
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 as contained in Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, which fall under
the "safe harbor" provisions of those sections. All statements,
other than statements of historical facts, may be forward-looking
statements. Forward-looking statements generally can be identified
by the use of forward-looking terminology such as "may," "might,"
"will," "should," "expect," "plan," "anticipate," "see," "could,"
"intend," "target," "project," "contemplate," "believe,"
"estimate," "predict," "potential" or "continue" or variations of
them or similar terminology, but the absence of these words does
not mean that a statement is not forward-looking. These
forward-looking statements include, but are not limited to,
statements regarding 10x Genomics, Inc.'s ("10x Genomics") and
others' product launches, performance, configuration, costs,
capabilities, requirements, workflows, adoption and pipeline. These
statements are based on management's current expectations,
forecasts, beliefs, assumptions and information currently available
to management, and actual outcomes and results could differ
materially from these statements due to a number of factors. Other
risks and uncertainties that could affect 10x Genomics' financial
and operating results and cause actual results to differ materially
from those indicated by the forward-looking statements made in this
press release include those discussed under the captions "Risk
Factors" and "Management's Discussion and Analysis of Financial
Condition and Results of Operations" and elsewhere in the documents
10x Genomics files with the Securities and Exchange Commission (the
"SEC") from time to time. Although 10x Genomics believes that the
expectations reflected in the forward-looking statements are
reasonable, it cannot provide any assurance that these expectations
will prove to be correct nor can it guarantee that the future
results, levels of activity, performance and events and
circumstances reflected in the forward-looking statements will be
achieved or occur. The forward-looking statements in this press
release are based on information available to 10x Genomics as of
the date hereof, and 10x Genomics disclaims any obligation to
update any forward-looking statements provided to reflect any
change in its expectations or any change in events, conditions or
circumstances on which any such statement is based, except as
required by law. These forward-looking statements should not be
relied upon as representing 10x Genomics' views as of any date
subsequent to the date of this press release.
Disclosure Information
10x Genomics uses filings with
the Securities and Exchange Commission, our website
(www.10xgenomics.com), press releases, public conference calls,
public webcasts and our social media accounts as means of
disclosing material non-public information and for complying with
our disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/10x-genomics-unveils-chromium-xo-a-low-cost-instrument-to-expand-access-to-high-performance-single-cell-research-302237175.html
SOURCE 10x Genomics, Inc.
